Despite the relatively high prevalence of hypertrophic cardiomyopathy (HCM), reported to be as high as 1 in 200 individuals, most individuals are undiagnosed and untreated. The pathophysiology of HCM is complex and consists of multiple interrelated abnormalities. In order to move the needle from an often-fatal condition to a treatable chronic condition, clinicians must be able to identify patients, understand the challenges of diagnosis, and implement new and emerging treatment options for their patients.
What is the underlying pathophysiology of HCM? How do you diagnose a patient with HCM? Are you treating patients according to current HCM guideline recommendations? What about cardiac myosin inhibitors – where do they fit into the treatment algorithm for HCM?
Join our panel of leading experts for a unique and interactive gameshow-style educational symposium on HCM to get the answers to all these questions, and guide your team to victory!
Associate Professor
Co-Director, Inherited Cardiomyopathy Program
Frankel Cardiovascular Center
University of Michigan Hospital, Michigan Medicine
Ann Arbor, Michigan
Professor of Medicine
Harvard Medical School
Section Head, Heart Failure
Director, Cardiopulmonary Exercise Testing Laboratory
Medical Director, Cardiac Transplantation Program
Mass General Hospital
Boston, Massachusetts
Director
Hypertrophic Cardiomyopathy Center
Lahey Hospital & Medical Center
Burlington, Massachusetts
Welcome and Introductions
Chairperson, Sara Saberi, MD, MS
HCM Game Show:
- Round 1 - HCM: Where Are We in 2024?
- Round 2 - Clinical Updates in HCM: Pearls for Cardiology Practice
- Round 3 - Case Consults: Integrating New Approaches
Panel Discussion and Q&A
In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Medscape, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Awarded 1.50 contact hour(s) of nursing continuing professional development for RNs and APNs.
Medscape designates this continuing education activity for 1.50 contact hour(s) (0.150 CEUs) (Universal Activity Number: JA0007105-0000-24-215-L01-P).
Upon completion of this activity, participants will:
Have increased knowledge regarding the:
- Unmet clinical needs of patients with HCM
- Mechanism of action (MOA) of CMIs to target the underlying pathology of HCM
- Recent clinical trial data for emerging HCM therapies
Have greater competence related to
- Identification of patients with HCM who may benefit from CMI therapy
Demonstrate greater confidence in their ability to
- Integrate CMIs into treatment plans for appropriate patients
This educational activity is presented through a collaboration between Medscape Cardiology and the Heart Failure Society of America. The program topic, learning objectives, and faculty have been reviewed and approved by HFSA.